CRISPR is leaving the lab faster than the ethics are keeping up

We now have approved CRISPR therapies for sickle cell. That's astonishing and barely made the news. Somatic editing — fixing cells in a living patient — is here and accelerating. Germline editing (heritable changes to embryos) is the bright line: technically increasingly feasible, ethically a minefield. My worry isn't the science; it's that access will be unequal and governance is fragmented. We should be having the "who decides" conversation now, loudly, before the tech forces it.